Artivion (NYSE:AORT) Receives Market Outperform Rating from JMP Securities

Artivion (NYSE:AORT)‘s stock had its “market outperform” rating restated by analysts at JMP Securities in a research note issued on Tuesday,Benzinga reports. They currently have a $33.00 price target on the stock. JMP Securities’ price objective suggests a potential upside of 12.59% from the stock’s previous close.

A number of other analysts also recently commented on AORT. Needham & Company LLC reissued a “buy” rating and set a $34.00 price objective on shares of Artivion in a report on Monday. Oppenheimer raised their price target on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Finally, Stifel Nicolaus lifted their price target on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a report on Friday, September 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Artivion has an average rating of “Buy” and a consensus target price of $31.80.

Artivion Stock Up 1.1 %

NYSE AORT traded up $0.31 during trading on Tuesday, reaching $29.31. 17,153 shares of the company’s stock were exchanged, compared to its average volume of 225,412. The company has a 50 day moving average price of $27.43 and a two-hundred day moving average price of $26.07. Artivion has a 1 year low of $16.48 and a 1 year high of $30.10. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. The stock has a market cap of $1.23 billion, a P/E ratio of -1,465.50 and a beta of 1.75.

Insider Buying and Selling at Artivion

In other Artivion news, CAO Amy Horton sold 4,329 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $29.66, for a total transaction of $128,398.14. Following the transaction, the chief accounting officer now directly owns 135,660 shares in the company, valued at $4,023,675.60. This trade represents a 3.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Andrew M. Green sold 7,618 shares of the company’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total transaction of $228,540.00. Following the sale, the vice president now directly owns 33,503 shares of the company’s stock, valued at approximately $1,005,090. This represents a 18.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 24,377 shares of company stock valued at $682,356. Corporate insiders own 8.10% of the company’s stock.

Hedge Funds Weigh In On Artivion

Institutional investors have recently modified their holdings of the stock. nVerses Capital LLC acquired a new position in Artivion in the 2nd quarter worth $28,000. Quarry LP increased its holdings in Artivion by 210.8% in the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock valued at $32,000 after buying an additional 820 shares during the period. RiverPark Advisors LLC bought a new stake in shares of Artivion during the second quarter worth $55,000. RW Investment Management LLC bought a new stake in Artivion during the 2nd quarter worth approximately $219,000. Finally, Intech Investment Management LLC bought a new stake in shares of Artivion in the 2nd quarter valued at $253,000. 86.37% of the stock is owned by institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.